# Safety, Tolerability and Pharmacokinetics of Multiple Doses of VAK694 in Atopic Subjects With Seasonal Rhinitis

> **NCT00929968** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 35 (actual)

## Conditions studied

- Allergic Rhinitis

## Interventions

- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** VAK694
- **DRUG:** Fluticasone

## Key facts

- **NCT ID:** NCT00929968
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2011-02
- **Final completion:** —
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00929968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00929968, "Safety, Tolerability and Pharmacokinetics of Multiple Doses of VAK694 in Atopic Subjects With Seasonal Rhinitis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00929968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*